The advent of effective immunotherapy and targeted therapy has significantly improved outcomes in advanced-stage resectable melanoma. Currently, the mainstay of treatment of malignant melanoma is surgery followed by adjuvant systemic therapies. However, recent studies have shown a potential role for neoadjuvant therapy in the treatment of advanced-stage resectable melanoma. Mechanistically, neoadjuvant immunotherapy may yield a more robust response than adjuvant immunotherapy, as the primary tumor serves as an antigen in this setting rather than only micrometastatic disease after the index procedure. Additionally, targeted therapy has been shown to yield effective neoadjuvant cytoreduction, and oncolytic viruses may also increase the immunogenicity of primary tumors. Effective neoadjuvant therapy may serve to decrease tumor size and thus reduce the extent of required surgery and thus morbidity. It also allows for assessment of pathologic response, facilitating prognostication as well as tailoring future therapy. The current literature consistently supports that neoadjuvant therapy, even as little as one dose, is associated with improved outcomes and is well-tolerated. Some patients with a complete pathological response may even avoid surgery completely. These results challenge the current paradigm of a surgery-first approach and provide further evidence supporting neoadjuvant therapy in advanced-stage resectable melanoma. Further research into the optimal treatment schedule and dose timing is warranted, as is the continued investigation of novel therapies and combinations of therapies.
Introduction: SETD2 is an understudied gene that encodes for a histone methyltransferase implicated in lung cancer tumorigenesis and is found in up to 10% of all non-small cell lung cancer. With the largest cohort to date, we aim to elucidate the clinicopathologic characteristics and prognosis of SETD2-mutated lung adenocarcinoma. Methods: We obtained molecular genetics reports of lung cancer seen between 1 January 2015 and 4 January 2024. We identified all SETD2-mutated cancer and identified 500 consecutive cases prior to 4 January 2020 as a control group. Non-recurrent adenocarcinomas were included. Patient and tumor characteristics and recurrence-free survival (RFS) were compared. Fisher’s exact, Wilcoxon rank sum, and log-rank tests were used when appropriate. Kaplan–Meier plots and Cox proportional hazards models were used to analyze recurrence-free survival. Results: A total of 67 SETD2-mutated lung and 174 non-SETD2-mutated lung adenocarcinomas met inclusion criteria. SETD2-mutated tumors presented at earlier stages (55.2% vs. 17.8% stage I, 11.9% vs. 48.3% stage IV, p < 0.001). SETD2-mutated adenocarcinoma had a higher number of genetic mutations (median: 11 IQR: [8–15] vs. 7 [5–10], p < 0.001). In a univariable Cox analysis, SETD2 mutation was associated with improved RFS (HR 0.53 95% CI: [0.33–0.85], p = 0.008). In a covariate-adjusted model, SETD2 mutation trended towards improved RFS (0.71 [0.43–1.18], p = 0.10). Conclusions: These data suggest SETD2-mutated lung adenocarcinoma presents at significantly earlier stages, has a unique molecular profile compared to non-mutated tumors, and trends towards improved RFS in early-stage tumors. Future study is warranted on both patient outcomes and immunopathologic characteristics of SETD2-mutated lung adenocarcinoma.
Lung cancer remains the leading cause of cancer-related death, and, despite significant advancements in targeted therapy and immunotherapy, survival for patients with advanced non-small cell lung cancer (NSCLC) remains poor. An emerging area of interest is the role of epigenetic modifiers in both the pathogenesis and treatment of NSCLC. Herein, we review a selected group of chromatin-modifying genes implicated in NSCLC, organized by their function as writers (KMT2A, SETD2, and EZH2), erasers (the KDM2, KDM5, and KDM6 demethylase families), and readers (the SWI/SNF subunits SMARCA4 and ARID1A). Writers deposit activating or repressive marks on histones to regulate gene transcription, erasers remove these marks, and readers reposition nucleosomes and control DNA accessibility. Dysregulation of these genes has been associated with tumor proliferation, metastasis, treatment resistance, and altered response to immune checkpoint blockade in NSCLC. Research within this topic is emerging, and these genes represent promising potential therapeutic avenues as well as potential biomarkers. Finally, we review the clinical trials involving targeting these genes available in the current literature. The number of NSCLC-specific trials remains limited, with the most active development in SMARCA2 inhibitors for SMARCA4-mutated tumors and EZH2 inhibitors given in tandem with PD-1 blockade. We hope this review is hypothesis-generating for ongoing investigation into the role of epigenetic modifiers in NSCLC and their potential to expand the therapeutic armamentarium available for this disease.
10 November 2025 in Surgical Oncology Clinics of North America